Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis

Abstract Background Daclizumab beta is a humanized monoclonal antibody specific for the human interleukin-2 receptor alpha chain (CD25). In two pivotal studies in relapsing multiple sclerosis (MS), patients treated with daclizumab beta exhibited lower annualized relapse rates (ARR) when compared wit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Multiple sclerosis and related disorders 2017-10, Vol.17, p.32-40
Hauptverfasser:	Rose, John W, Giovannoni, Gavin, Wiendl, Heinz, Gold, Ralf, Havrdová, Eva, Kappos, Ludwig, Selmaj, Krzysztof W, Zhao, Jun, Riester, Katherine, Tsao, L. Claire, Greenberg, Steven J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Annualized relapse rate Antibodies, Monoclonal, Humanized - therapeutic use Daclizumab beta Female Humans Immunoglobulin G - therapeutic use Interferon beta-1a Magnetic Resonance Imaging Male Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - pathology Neurology Relapsing-remitting multiple sclerosis Subgroup analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!